MedTech M&A-Report Q1 2025
MedTech M&A gains pace – strategic interest sets tone for 2025
Switzerland’s MedTech sector continues to demonstrate remarkable resilience and strong investor appeal.
In our latest report, we examine recent market trends, valuation expectations, and transaction activity — with a particular focus on Switzerland’s position in an international context.
Key insights at a glance:
- Strategic buyers continue to dominate deal activity — especially in transactions exceeding CHF 50 million
- Valuation levels remain stable and above the historical median
- Growing cross-border interest in Swiss MedTech companies
- Recent transaction examples and case studies — including MIS Healthcare’s acquisition of Xiel
Read the full report to discover how the market is shaping up for 2025.
Feel free to reach out to our experts to discuss any questions or areas of interest. We would be pleased to explore how Oaklins can create value for you through our strong international network. Our team is at your disposal to address your specific M&A and corporate finance objectives.
Your contact persons
Partner
View profile
Analyst
View profile
Completed M&A transactions in the healthcare sector